By: Benzinga
UPDATE: Jefferies Raises PT on Celldex Therapeutics on Encouraging Pipeline Outlook
In a report published Friday, Jefferies reiterated its Buy rating on Celldex Therapeutics (NASDAQ: CLDX ), and raised its price target from $9.00 to $15.00. Jefferies noted, “CLDX provided an encouraging overall pipeline outlook including a risk-mitigated CDX-011 registrational strategy, and favorable rindopepimut and CDX-1135 updates. We believe CLDX represents
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here